Get the Stockscreener App
6.57
1.79%
-0.12
Novavax Inc stock is traded at $6.57, with a volume of 2.92M.
It is down -1.79% in the last 24 hours and down -8.75% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$6.69
Open:
$6.7
24h Volume:
2.92M
Relative Volume:
0.70
Market Cap:
$1.07B
Revenue:
$1.08B
Net Income/Loss:
$422.82M
P/E Ratio:
2.8816
EPS:
2.28
Net Cash Flow:
$-637.33M
1W Performance:
-4.92%
1M Performance:
-8.75%
6M Performance:
-8.11%
1Y Performance:
-27.16%
1-Day Range:
$6.4301
$6.71
1-Week Range:
$6.4301
$7.035
52-Week Range:
$5.01
$11.55
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
6.57 | 1.09B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback? - ts2.tech
Revenue Check: Why Novavax Inc stock is trending among retail traders2025 Top Decliners & Stepwise Swing Trade Plans - moha.gov.vn
CDC study finds COVID shot significantly reduced ER visits for children - Seeking Alpha
Why I wouldn't touch Novavax with a 10-foot pole - MSN
Why I Wouldn't Touch Novavax With a 10-Foot Pole - Nasdaq
Novavax Inc. Stock Underperforms Tuesday When Compared To Competitors - 富途牛牛
Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - Yahoo Finance
Lobbying Update: $30,000 of NOVAVAX lobbying was just disclosed - Quiver Quantitative
Novavax, Inc. (NVAX): A Bull Case Theory - Finviz
Novavax, Inc. (NVAX): A bull case theory - MSN
Will Novavax Inc. (NVV1) stock deliver stable dividendsMarket Movement Recap & Verified Technical Signals - Newser
How Novavax Inc. (NVV1) stock benefits from digital adoptionJuly 2025 Action & Weekly Breakout Watchlists - Newser
How Novavax Inc. (NVV1) stock gains from tech spendingRisk Management & Weekly Stock Performance Updates - Newser
Novavax (NVAX): Exploring Valuation After Prolonged Share Price Weakness - Yahoo Finance
Why pension funds invest in Novavax Inc. (NVV1) stockEarnings Summary Report & Long-Term Growth Plans - Newser
Discipline and Rules-Based Execution in NVAX Response - news.stocktradersdaily.com
Bank of America Securities Sticks to Their Sell Rating for Novavax (NVAX) - The Globe and Mail
Why Novavax Inc. stock could see breakout soonWeekly Trend Summary & AI Forecasted Stock Moves - Newser
How Novavax Inc. (NVV1) stock reacts to Fed tighteningInsider Selling & Verified Swing Trading Watchlist - Newser
Vaccine developers’ stocks dip after Prasad memo becomes public - BioCentury
Moderna, Novavax Shares Fall on News FDA Plans to Tighten Vaccine Approvals - The Wall Street Journal
Moderna and Novavax Stocks Drop as FDA Outlines Stricter Vaccine Approvals - Barron's
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals - Barron's
Moderna Falls as FDA Vows to Impose New Vaccine Requirements - Bloomberg.com
Cash from financing activities of Novavax, Inc. – SIX:NVAX.USD - TradingView
Intech Investment Management LLC Sells 58,151 Shares of Novavax, Inc. $NVAX - MarketBeat
What drives Global Ship Lease Inc stock priceReal-Time Stock Alerts & Capital Efficiency Improvement - earlytimes.in
Will Novavax Inc. stock outperform international peersJuly 2025 Trends & Technical Pattern Recognition Alerts - BỘ NỘI VỤ
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Should You Follow Insider Buying Trends for India Steel Works LimitedWeekly Market Snapshot & Free Stock Index Interpretations - earlytimes.in
What drives Novavax Inc stock priceMarket Profile Overview & Free Explosive Return Secrets - earlytimes.in
Can Ganga Papers India Limited Maintain Shareholder Returns via BuybacksEmerging Market Stocks & Superior Trading Portfolio - earlytimes.in
Novavax Inc. Stock Climbs 3.9%, Outperforms Peers - 富途牛牛
Novavax Shifts From COVID Sales to R&D Focus While Updating 2025 Forecast - MSN
Shah Capital continues push for potential Novavax sale - Alternatives Watch
Milestones Over Sales: The Sanofi Partnership Now Drives Novavax’s Outlook (NVAX) - Seeking Alpha
January 2026 Options Now Available For Novavax (NVAX) - Nasdaq
Novavax’s R&D Shift and Sanofi Partnership Could Be a Game Changer for NVAX - Yahoo Finance
What Recent Partnership Efforts Mean for the Value of Novavax in 2025 - Yahoo Finance
Novavax slips as Citi launches with Sell rating on pipeline concerns - MSN
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now? - sharewise.com
Novavax Inc. stock rises Monday, still underperforms market - MarketWatch
9 Oversold Biotech Stocks to Invest In - Insider Monkey
Novavax rises after a seven-day slide - MSN
Behavioral Patterns of NVAX and Institutional Flows - news.stocktradersdaily.com
Novavax, UniFirst, and More Stocks See Action From Activist Investors - Barron's
Interesting NVAX Put And Call Options For July 2026 - Nasdaq
How rising interest rates impact Novavax Inc. stockWeekly Risk Report & Reliable Intraday Trade Alerts - newser.com
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):